Replies to post #195706 on Biotech Values

[flatlander_60048]

GHDX was down 11% at one point possibly coincidental with Exas and/or ILMN (reduced genetic testing reimbursement) or overall biotech weakness.

Urology Review suggests that the Prostate test which recently received CMS billing code last month could fill a very unmet need.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274174/

Looks like the diagnostic stocks that never had the run up are getting tarred with the same brush being used on the rest of biotech.


FL